Introduction GLP1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) work by mimicking a hormone your body already makes called glucagon-like peptide-1
The Osteoarthritis Initiative, a long-term observational study tracking over 4,000 joint disease patients, revealed that sustained weight loss of 10 pounds or more correlated with slower cartilage degradation on imaging and reduced pain medication use
Thirteen of the patients met criteria for residual schizophrenia (see SA6 for details of exclusions and a discussion relating to our sample size, clinical and demographic features of the sample are reported in ST4)
Hales C, Carroll M, Fryar CD, et al
Rising Global Metabolic Disease Burden Driving Strong Structural Demand for GLP-1 Therapies Growth of the GLP-1 receptor agonist market is mainly attributed to the rising prevalence of Type 2 diabetes and obesity on a global scale